Prelude Therapeutics Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: PRLD · Form: DEF 14A · Filed: Apr 26, 2024 · CIK: 1678660
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Director Election, Auditor Ratification, Virtual Meeting
TL;DR
<b>Prelude Therapeutics Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to elect directors and ratify auditor appointments.</b>
AI Summary
Prelude Therapeutics Inc (PRLD) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. The 2024 Annual Meeting of Stockholders for Prelude Therapeutics Inc. will be held virtually on June 14, 2024, at 11:30 a.m. Eastern Time. Stockholders will vote on the election of two Class I directors for three-year terms. The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024 will be ratified. Stockholders of record as of April 18, 2024, are entitled to vote. A list of stockholders entitled to vote will be available for review for ten days prior to the meeting.
Why It Matters
For investors and stakeholders tracking Prelude Therapeutics Inc, this filing contains several important signals. This filing is a proxy statement, indicating key corporate governance decisions are being presented to shareholders for a vote. The virtual meeting format allows for broader participation from stockholders regardless of location.
Risk Assessment
Risk Level: — Prelude Therapeutics Inc shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information, thus posing a low risk.
Analyst Insight
Stockholders should review the director nominees and auditor ratification to make informed voting decisions.
Key Numbers
- 2 — Directors to be elected (Two Class I directors to serve three-year terms)
- 2027 — Director term end year (Class I directors to serve through the 2027 annual meeting)
Key Players & Entities
- Prelude Therapeutics Inc. (company) — Registrant and filer of the proxy statement
- June 14, 2024 (date) — Date of the Annual Meeting of Stockholders
- Ernst & Young LLP (company) — Proposed independent registered public accounting firm
- April 18, 2024 (date) — Record date for stockholders entitled to vote
FAQ
When did Prelude Therapeutics Inc file this DEF 14A?
Prelude Therapeutics Inc filed this Proxy Statement (DEF 14A) with the SEC on April 26, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Prelude Therapeutics Inc (PRLD).
Where can I read the original DEF 14A filing from Prelude Therapeutics Inc?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Prelude Therapeutics Inc.
What are the key takeaways from Prelude Therapeutics Inc's DEF 14A?
Prelude Therapeutics Inc filed this DEF 14A on April 26, 2024. Key takeaways: The 2024 Annual Meeting of Stockholders for Prelude Therapeutics Inc. will be held virtually on June 14, 2024, at 11:30 a.m. Eastern Time.. Stockholders will vote on the election of two Class I directors for three-year terms.. The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024 will be ratified..
Is Prelude Therapeutics Inc a risky investment based on this filing?
Based on this DEF 14A, Prelude Therapeutics Inc presents a moderate-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information, thus posing a low risk.
What should investors do after reading Prelude Therapeutics Inc's DEF 14A?
Stockholders should review the director nominees and auditor ratification to make informed voting decisions. The overall sentiment from this filing is neutral.
How does Prelude Therapeutics Inc compare to its industry peers?
Prelude Therapeutics Inc. operates in the pharmaceutical preparations industry, focusing on developing novel therapies.
Are there regulatory concerns for Prelude Therapeutics Inc?
This filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
Risk Factors
- Proxy Statement Filing [low — regulatory]: The filing is a routine DEF 14A proxy statement for the annual meeting of stockholders.
Industry Context
Prelude Therapeutics Inc. operates in the pharmaceutical preparations industry, focusing on developing novel therapies.
Regulatory Implications
This filing is made under Section 14(a) of the Securities Exchange Act of 1934, governing proxy solicitations.
What Investors Should Do
- Review the biographies and qualifications of the director nominees.
- Evaluate the independence and qualifications of Ernst & Young LLP.
- Vote on the election of directors and the ratification of the auditor appointment.
Key Dates
- 2024-06-14: Annual Meeting of Stockholders — Election of directors and ratification of auditor appointment
- 2024-04-18: Record Date — Determines which stockholders are entitled to vote at the meeting
Year-Over-Year Comparison
This is the initial filing for the 2024 Annual Meeting of Stockholders, providing details on upcoming votes and meeting logistics.
Filing Stats: 4,553 words · 18 min read · ~15 pages · Grade level 13.9 · Accepted 2024-04-26 16:11:14
Filing Documents
- def_proxy_2024.htm (DEF 14A) — 634KB
- img116409515_0.jpg (GRAPHIC) — 5KB
- img116409515_1.jpg (GRAPHIC) — 79KB
- img116409515_2.jpg (GRAPHIC) — 71KB
- 0000950170-24-049126.txt ( ) — 849KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 18 EXECUTIVE OFFICERS 21
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 22 EQUITY COMPENSATION PLAN INFORMATION 26 CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS 27 ADDITIONAL INFORMATION 28 OTHER MATTERS 29 WEBSITE ADDRESSES Website addresses referenced in this Proxy Statement are inactive textual references only, and the content on the referenced websites specifically does not constitute a part of this Proxy Statement. CAUTIONARY STATEMENTS REGARDING FORWARD-LOOKING INFORMATION This Proxy Statement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “may,” “estimate,” “intend,” and other similar words. We base these forward-looking statements on our beliefs, assumptions, and estimates using information available to us at the time. They are not intended to be guarantees of future events or performance. Factors that may cause actual results to differ materially from forward-looking statements in this Proxy Statement can be found in our most recent Annual Report on Form 10-K filed with the SEC on February 15, 2024 and in our subsequent filings with the SEC, including under the headings “Risk Factors” and “Forward-Looking Statements.” We caution you not to unduly rely on any of our forward-looking statements. We disclaim any intention or obligation to publicly update or revise any forward-looking statements, except as required by law. This cautionary statement applies to all forward-looking statements contained in this document. PRELUDE THERAPEUTICS INCORPORATED 175 Innovation Boulevard Wilmington, Delaware 19805 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKH